title: Gemcitabine for relapsed or resistant lymphoma.
abstract: BACKGROUND
  Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma.
  
  
  METHODS
  Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment. The drug was then given for 3 consecutive weeks, followed by a week off treatment; this regimen was continued until disease progression or drug intolerance. Fifteen patients have enrolled. Most have been extensively pre-treated for advanced diffuse large-cell or mantle-cell lymphoma.
  
  
  RESULTS
  The drug was well tolerated; no patient suffered treatment-related sepsis, hemorrhage or death. Non-hematopoietic toxicity led to discontinuation of gemcitabine therapy in two patients. Dose reductions or delays were required for about two-thirds of treatments. Of 13 evaluable patients, one had a complete response, 3 a partial response, 3 stable disease, and 6 disease progression. After 6 infusions of gemcitabine, a patient with advanced Hodgkin's disease has had a complete remission lasting 21 months.
  
  
  CONCLUSIONS
  Gemcitabine has substantial activity and acceptable toxicity in heavily pre-treated patients with advanced lymphoma. Further study is warranted.
authors.affiliation: Hematology/Oncology Division, Columbia University, New York, New York 10032, USA. savage@cuccfa.ccc.columbia.edu
authors.forename: D G
authors.initials: DG
authors.lastname: Savage
authors.forename: S A
authors.initials: SA
authors.lastname: Rule
authors.forename: M
authors.initials: M
authors.lastname: Tighe
authors.forename: T J
authors.initials: TJ
authors.lastname: Garrett
authors.forename: M W
authors.initials: MW
authors.lastname: Oster
authors.forename: R T
authors.initials: RT
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Ruiz
authors.forename: D
authors.initials: D
authors.lastname: Heitjan
authors.forename: M L
authors.initials: ML
authors.lastname: Keohan
authors.forename: M
authors.initials: M
authors.lastname: Flamm
authors.forename: S A
authors.initials: SA
authors.lastname: Johnson
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine